Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
In contrast, preoperative GLP-2 plasma concentrations did not differ, but increased 3.4-fold within the first postoperative day in patients with PHLF, compared to an 1.5-times increase in patients who did not develop PHLF, resulting in 2.0-times higher GLP-2 level in PHLF on POD1 ( p = 0.008)
It's another to keep it off
Back Laughton, NB, Macallum, AB (1 June 1932) 'The Relation of duodenal mucosa to internal secretion of the pancreas', Proceedings of the Royal Society of London
Can microdosing GLP-1s help with reducing side effects
Historically, state Medicaid programs, state employee health plans and a myriad of other insurers have provided coverage of GLP-1s to treat Type 2 Diabetes